Millennium Management LLC Has $4.73 Million Holdings in Artivion, Inc. (NYSE:AORT)

Millennium Management LLC increased its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 25.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,482 shares of the company's stock after purchasing an additional 33,220 shares during the quarter. Millennium Management LLC owned 0.39% of Artivion worth $4,731,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after purchasing an additional 786 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Artivion during the fourth quarter valued at approximately $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion during the fourth quarter valued at approximately $43,000. Venturi Wealth Management LLC acquired a new stake in shares of Artivion during the fourth quarter valued at approximately $78,000. Finally, KBC Group NV raised its holdings in shares of Artivion by 80.4% during the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock valued at $80,000 after acquiring an additional 1,254 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 8,748 shares of the stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total transaction of $253,692.00. Following the transaction, the senior vice president now owns 178,510 shares in the company, valued at $5,176,790. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John E. Davis sold 15,100 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the transaction, the insider now owns 208,778 shares in the company, valued at approximately $4,929,248.58. This trade represents a 6.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,414 shares of company stock valued at $1,716,731 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Artivion Stock Down 2.8%

Artivion stock traded down $0.84 during trading hours on Monday, hitting $28.74. The company had a trading volume of 505,878 shares, compared to its average volume of 330,736. The firm has a market capitalization of $1.23 billion, a P/E ratio of -1,437.00 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm's fifty day moving average is $25.70 and its 200-day moving average is $27.40. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). The company had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of recent analyst reports. Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Needham & Company LLC restated a "buy" rating and set a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.